Read our newest white paper from MERIT’s imaging science team and leading retina KOLs. Could MERIT’s Outer Retina-Choroid (ORC™), a proprietary en face OCT-based image, be a better structural endpoint than fundus autofluorescence (FAF) for dry AMD clinical trials? The white paper digs into exactly that question, with a particular focus on trial designs that pair structural imaging with functional endpoints. The findings have notable implications for how sponsors think about endpoint selection in dry AMD programs.